Side-by-side comparison of AI visibility scores, market position, and capabilities
P&G's flagship oral care brand competing with Colgate; 3D Whitestrips at-home whitening franchise dominates premium whitening segment in two-brand toothpaste market oligopoly.
Crest is Procter & Gamble's flagship oral care brand, producing toothpaste, teeth whitening products (Crest 3D Whitestrips), electric toothbrush systems (Oral-B, co-branded), mouthwash, and floss — competing with Colgate for US and global toothpaste market leadership in a two-brand oligopoly that has dominated oral care for decades. Part of Procter & Gamble (NYSE: PG), one of the world's largest consumer goods companies with approximately $84 billion in annual revenue, Crest is one of P&G's largest and most profitable brands.\n\nCrest's product architecture spans fluoride toothpaste (Crest Cavity Protection, Crest Complete), sensitivity relief (Crest Gum and Sensitivity, formulated with stannous fluoride), whitening (Crest 3D White), prescription-strength (Crest Pro-Health), and premium (Crest brilliance pro). The 3D Whitestrips at-home whitening franchise is one of the most successful category innovations in oral care — creating a premium whitening segment worth billions that Crest dominates. Crest is sold through grocery, drug, and mass merchandise retailers globally.\n\nIn 2025, Crest competes with Colgate-Palmolive (the global toothpaste market leader by volume) for oral care market share. The oral care market has seen premiumization with sensitivity and whitening products growing faster than basic fluoride toothpaste, and new entrants like Hello Products (natural positioning), Arm & Hammer (baking soda), and Sensodyne (GSK/Haleon) competing in specific benefit segments. Crest's 2025 strategy focuses on the 3D Whitestrips franchise (launching new formats and expanding internationally), growing the sensitivity relief segment, and defending against natural and premium challenger brands.
Richmond VA tobacco and nicotine (NYSE: MO) ~$9.7B net revenue FY2024; Marlboro 40%+ US cigarette share, on! oral pouch competing with Zyn, 50%+ operating margins, ABI stake, competing with Reynolds/BAT.
Altria Group, Inc. is a Richmond, Virginia-based tobacco and nicotine company — publicly traded on the New York Stock Exchange (NYSE: MO) as an S&P 500 Consumer Staples component — manufacturing and selling cigarettes (Marlboro — the best-selling cigarette brand in the United States), smokeless tobacco (Copenhagen, Skoal, Red Seal, Husky chewing tobacco/moist snuff brands), oral nicotine pouches (on! brand), and maintaining a 10.7% ownership stake in Anheuser-Busch InBev (SABMiller acquisition consideration shares) and a 35% stake in JUUL Labs (vaping — original $12.8B investment written down to minimal value following JUUL's regulatory and litigation difficulties) through approximately 5,500 employees. In fiscal year 2024, Altria reported revenues of approximately $20.6 billion (net revenues after excise taxes approximately $9.7 billion), with the cigarette segment (Marlboro generating 40%+ US cigarette market share) contributing the majority of operating income at 50%+ adjusted operating margins — the highest margins in the consumer staples sector reflecting cigarettes' inelastic demand and regulated market structure. CEO Billy Gifford has pivoted Altria's strategy from cigarettes toward smoke-free nicotine products: the on! oral nicotine pouch (acquired full ownership of Helix Innovations in 2023, rebranding as on! to compete with Swedish Match Zyn, the dominant US oral nicotine pouch brand) represents Altria's primary nicotine product diversification vehicle as cigarette volume declines 7-8% annually through consumer quit rates and secular health awareness trends.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.